These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 12429797)

  • 41. The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan.
    Lai YS; Cheng CC; Lee MT; Chao WT; Lai YC; Hsu YH; Liu YH
    Int J Med Sci; 2018; 15(14):1746-1756. PubMed ID: 30588199
    [No Abstract]   [Full Text] [Related]  

  • 42. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.
    Zen Y; Sasaki M; Fujii T; Chen TC; Chen MF; Yeh TS; Jan YY; Huang SF; Nimura Y; Nakanuma Y
    J Hepatol; 2006 Feb; 44(2):350-8. PubMed ID: 16360234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma.
    Uenishi T; Yamazaki O; Yamamoto T; Hirohashi K; Tanaka H; Tanaka S; Hai S; Kubo S
    J Hepatobiliary Pancreat Surg; 2005; 12(6):479-83. PubMed ID: 16365823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
    Aishima S; Fujita N; Mano Y; Kubo Y; Tanaka Y; Taketomi A; Shirabe K; Maehara Y; Oda Y
    Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype.
    Nomoto K; Tsuneyama K; Cheng C; Takahashi H; Hori R; Murai Y; Takano Y
    Pathol Res Pract; 2006; 202(2):71-6. PubMed ID: 16377099
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant expression of alpha-fetoprotein in intrahepatic cholangiocarcinoma: an exceptional occurrence.
    Vij K; Wang HL
    Int J Surg Pathol; 2008 Apr; 16(2):194-8. PubMed ID: 18417680
    [TBL] [Abstract][Full Text] [Related]  

  • 48. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma.
    Varnholt H; Asayama Y; Aishima S; Taguchi K; Sugimachi K; Tsuneyoshi M
    Oncol Rep; 2002; 9(1):35-41. PubMed ID: 11748452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
    Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
    Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
    Zhang F; Chen XP; Zhang W; Dong HH; Xiang S; Zhang WG; Zhang BX
    Histopathology; 2008 Jan; 52(2):224-32. PubMed ID: 18184271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metastatic colon cancer from intrahepatic cholangiocarcinoma.
    Wakahara T; Tsukamoto T; Kitamura S; Watanabe A; Tsujimura T; Nakamura Y; Toyokawa A; Onishi N; Hamabe Y; Mukai H; Teramura K
    J Hepatobiliary Pancreat Surg; 2005; 12(5):415-8. PubMed ID: 16258812
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Kim KH; Lee SG; Park EH; Hwang S; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    Ann Surg Oncol; 2009 Mar; 16(3):623-9. PubMed ID: 19130133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
    Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
    J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma.
    Nakagohri T; Asano T; Kinoshita H; Kenmochi T; Urashima T; Miura F; Ochiai T
    World J Surg; 2003 Mar; 27(3):289-93. PubMed ID: 12607053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intrahepatic cholangiocarcinoma: new insights in pathology.
    Sempoux C; Jibara G; Ward SC; Fan C; Qin L; Roayaie S; Fiel MI; Schwartz M; Thung SN
    Semin Liver Dis; 2011 Feb; 31(1):49-60. PubMed ID: 21344350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathology of combined hepatocellular-cholangiocarcinoma.
    Yeh MM
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas: report of two cases and review of the literature.
    Xu AM; Xian ZH; Zhang SH; Chen XF
    Eur J Gastroenterol Hepatol; 2009 May; 21(5):580-4. PubMed ID: 19282767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
    Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
    Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.